- |||||||||| Litx (talaporfin) / Light Sciences Oncology, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Review, Journal: Early investigational agents for the treatment of benign prostatic hyperplasia'. (Pubmed Central) - Apr 8, 2024
More specifically, sheds light upon drug categories such as reductase?adrenoceptor antagonists, drugs interfering with the nitric oxide (NO)/cyclic guanosine monophosphate (GMP) signaling pathway, onabotulinumtoxinA, vitamin D3 (calcitriol) analogues, selective cannabinoid (CB) receptor agonists, talaporfin sodium, inhibitor of transforming growth factor beta 1 (TGF-?1), drugs targeting the hormonal control of the prostate, phytotherapy and many more. Clinical trials are being conducted on a number of new medications that may emerge as effective therapeutic alternatives in the upcoming years.
- |||||||||| Tavegil (clemastine) / GSK
Journal: Prolonged myelin deficits contribute to neuron loss and functional impairments after ischaemic stroke. (Pubmed Central) - Apr 8, 2024
Conversely, enhancing remyelination by M1R cKO or treating the pro-myelination drug clemastine after tMCAO preserves white matter integrity and neuronal survival, and accelerates functional recovery. Together, our findings demonstrate that enhancing myelinogenesis is a promising strategy to preserve neurons and promote functional recovery after ischemic stroke.
- |||||||||| Bexxar (iodine I 131 tositumomab) / GSK, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Review, Journal, IO biomarker: A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma. (Pubmed Central) - Apr 8, 2024
The combination of prolonged efficacy, tolerability, and treatment convenience makes RIT a reasonable alternative to other systemic therapies. It is recommended that further research on RIT should focus on biomarkers of long-term response, pretargeting, and sequencing of RIT in the treatment course.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Journal: New Daily Persistent Headache. (Pubmed Central) - Apr 7, 2024
Symptomatic treatment for new daily persistent headache may include acute and preventive therapies used for migraine and tension-type headache, such as triptans, oral preventive agents, onabotulinumtoxinA, and agents that target calcitonin gene-related peptide...The underlying cause is unknown, but it is plausible that multiple etiologies exist and that it is not a single disease entity. The prognosis is variable but often poor, and the treatment approach is largely extrapolated from the management of chronic migraine and chronic tension-type headache.
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
Journal: Community-Based Cross-Sectional Assessment Survey On Herpes Zoster Vaccination Practices. (Pubmed Central) - Apr 7, 2024
Our study aims at assessing the knowledge, attitudes practices beliefs and current barriers towards the Shingrix vaccine to fully understand where we stand and come up with proper recommendations to services these at-risk individuals and ultimately have a positive impact on the healthcare system...Most of the participants had minimal knowledge regarding the vaccine and were willing to take it regardless of some safety concerns. more efforts need to be conducted to enhance vaccine uptake in at risk populations in Saudi Arabia.
- |||||||||| Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena. (Pubmed Central) - Apr 6, 2024
In our new multidisciplinary guideline osteoporosis and fracture prevention, we developed 5 "relatively new statements" that are all a crucial step forward in the optimization of diagnosis and treatment for fracture prevention. We also developed 5 flowcharts, and we suppose that this may be helpful for individual doctors and their patients in daily practice and may facilitate implementation.
- |||||||||| Halfan (halofantrine) / GSK
Preclinical, Journal: Quantifying the Lymphatic Transport of Model Therapeutics from the Brain in Rats. (Pubmed Central) - Apr 5, 2024
Similar to other tissues, the lymphatics may thus play a significant role in the transport of macromolecules, including therapeutic proteins, from the brain but are unlikely to be a major transport pathway from the brain for small molecule drugs that are not lipophilic. Our rat cervical lymph cannulation model can be used to quantify the lymphatic drainage of different molecules and factors from the brain.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Clinical: Allogeneic mesenchymal stem cells may be a viable treatment modality in cerebral palsy. (Pubmed Central) - Apr 5, 2024
Our rat cervical lymph cannulation model can be used to quantify the lymphatic drainage of different molecules and factors from the brain. In light of our findings, we believe that UC-MSC therapy has a positive effect on spasticity, and it partially improves motor functions.
- |||||||||| Mosquirix (RTS,S) / GSK
Journal: Previous Malaria Exposures and Immune Dysregulation: Developing Strategies To Improve Malaria Vaccine Efficacy in Young Children. (Pubmed Central) - Apr 5, 2024
After several decades in development, two malaria vaccines based on the same antigen and with very similar constructs and adjuvants, RTS,S/AS01 (RTS,S) and R21/Matrix-M (R21), were recommended by the WHO for widespread vaccination of children...We highlight recent evidence suggesting that increasing malaria exposure impairs the generation of functional antibody responses to RTS,S. Finally, we discuss how investigation of clinical and immune factors associated with suboptimal responses to RTS,S can be used to develop strategies to optimize RTS,S, which will remain relevant to R21 and next-generation vaccines.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment closed, Trial completion date, Trial primary completion date: The Efficacy of Botulinum Toxin vs. Corticosteroid for the Treatment of Refractory Plantar Fasciitis (clinicaltrials.gov) - Apr 5, 2024
P2/3, N=62, Active, not recruiting,
Finally, we discuss how investigation of clinical and immune factors associated with suboptimal responses to RTS,S can be used to develop strategies to optimize RTS,S, which will remain relevant to R21 and next-generation vaccines. Recruiting --> Active, not recruiting
- |||||||||| otelixizumab (ChAglyCD3) / GSK
Journal: Trx4, a novel thioredoxin protein, is important for Toxoplasma gondii fitness. (Pubmed Central) - Apr 4, 2024
Combining the TurboID system with CRISPR-Cas9 technique revealed many PV-localized proximity proteins associated with Trx4. These findings suggest a versatile role of Trx4 in mediating the processes that occur in this distinctive intracellular membrane-bound vacuolar compartment.
- |||||||||| Prolia (denosumab) / Amgen
Journal: Sclerotic bone: a sign of bone reaction in patients with medication related osteonecrosis of the jaw. (Pubmed Central) - Apr 4, 2024
Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction associated with antiresorptive drugs such as bisphosphonates and denosumab...The pre and postoperative density showed no significant correlation to healing behaviour. The focus of the modelling osteotomy in surgical treatment of mature MRONJ lesions should be predominantly on the parts that appear necrotic and less dense in the panoramic radiograph as sclerotic areas might be an expression of bone reaction.
- |||||||||| GSK5733584 / GSK
Trial completion date, Trial primary completion date, Metastases: A Study of HS-20089 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 4, 2024
P1, N=177, Recruiting,
The focus of the modelling osteotomy in surgical treatment of mature MRONJ lesions should be predominantly on the parts that appear necrotic and less dense in the panoramic radiograph as sclerotic areas might be an expression of bone reaction. Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| Ogsiveo (nirogacestat) / SpringWorks Therap, Blenrep (belantamab mafodotin-blmf) / GSK
Biomarker, Journal, IO biomarker: Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma. (Pubmed Central) - Apr 4, 2024
Based on the proposed mechanism, pinocytosis-induced keratopathy can be prevented by lowering the entry of sBCMA into the lacrimal fluid. Future therapeutic concepts may therefore consist of belantamab-free debulking therapy prior to belantamab consolidation and/or concomitant use of gamma-secretase inhibition as currently evaluated for belantamab and nirogacestat in ongoing studies.
- |||||||||| Prolia (denosumab) / Amgen
Journal: Giant Cell Tumor of Mandible : A Case Report. (Pubmed Central) - Apr 3, 2024
After exclusion of distant metastasis by F-18 FDG PET scan, she underwent en-bloc resection of the tumor with free fibula flap reconstruction. During 6 months of follow up visit patient had no recurrence.
- |||||||||| Prolia (denosumab) / Amgen
Journal: Recurrent Giant Cell Tumor of Sphenoid Bone: A Rare Finding. (Pubmed Central) - Apr 3, 2024
Here, we describe a case of recurrent giant cell tumor of sphenoid bone in a young male, who underwent surgical resection twice, after which he was advised adjuvant radiotherapy and denosumab. The patient did not take radiotherapy.
- |||||||||| erastin - Whitehead Institute for Biomedical Research, Dana / Farber Cancer Institute, Columbia University, Prolexys
Preclinical, Journal: BRD4 inhibitors broadly promote erastin-induced ferroptosis in different cell lines by targeting ROS and FSP1. (Pubmed Central) - Apr 2, 2024
Our results suggest that ROS accumulation and FSP1 downregulation are common mechanisms underlying increased ferroptosis with BRD4 inhibitors. Thus, BRD4 inhibitors might be more effective in combination with ferroptosis inducers, especially in FSP1-dependent cancer cells.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap, Qulipta (atogepant) / AbbVie
Clinical Effectiveness of Atogepant with Onabotulinum Toxin Type A in Treatment of Chronic Migraine (Colorado Convention Center | Exhibit Hall B-E) - Apr 2, 2024 - Abstract #AAN2024AAN_4941;
Thus, BRD4 inhibitors might be more effective in combination with ferroptosis inducers, especially in FSP1-dependent cancer cells. This study provides preliminary evidence on the benefits of add on therapy with atogepant in patients with chronic migraine who are already on onabotulinum toxin type A.
- |||||||||| Prolia (denosumab) / Amgen, Tagrisso (osimertinib) / AstraZeneca
Retrospective data, Journal: Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy. (Pubmed Central) - Apr 2, 2024
The presence of BoM is a negative prognostic factor for NSCLC patients with an EGFR mutation, possibly due to the presence of extrathoracic metastases. However, adding AAT and denosumab, along with sequential osimertinib, to the treatment regimen for patients with BoM can improve survival outcomes.
- |||||||||| Arexvy (respiratory syncytial virus vaccine, adjuvanted) / GSK
Review, Journal: Vaccines for Respiratory Syncytial Virus Prevention in Older Adults. (Pubmed Central) - Apr 2, 2024
A literature search through February 27, 2024 was conducted using search terms, such as RSV, viral respiratory illness, vaccine, RSVpreF, RSVpreF3, Prefusion F, Abrysvo, and Arexvy...Administration requires a single intramuscular injection of 0.5 mL, reconstituted prior to administration. The RSVpreF3-ASO1E and RSVpreF vaccines effectively prevent RSV-associated LRTD in adults aged 60 years and older.
- |||||||||| seasonal influenza vaccine (mRNA-1010) / Moderna
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults (clinicaltrials.gov) - Apr 2, 2024
P2, N=98, Active, not recruiting,
The RSVpreF3-ASO1E and RSVpreF vaccines effectively prevent RSV-associated LRTD in adults aged 60 years and older. Completed --> Active, not recruiting | N=68 --> 98 | Trial completion date: Jan 2024 --> Aug 2024 | Trial primary completion date: Jan 2024 --> Aug 2024
- |||||||||| Fasenra (benralizumab) / AstraZeneca
Journal: Sustained Effectiveness of Benralizumab in Na (Pubmed Central) - Apr 2, 2024
P=N/A
The mepolizumab subset was characterized by the longest SEA duration (median of 4.6 years), the highest prevalence of chronic rhinosinusitis with nasal polyposis (CRSwNP) (76.5%), and the greatest oral corticosteroid (OCS) daily dosage (median of 25 mg prednisone equivalent). Asthma Control Test (ACT) score improved in the na
- |||||||||| GSK692342 / GSK, Bill & Melinda Gates Foundation
Journal: Momentum of hope: The journey toward a universal TB vaccine. (Pubmed Central) - Apr 2, 2024
Recent developments, such as the M72/AS01E vaccine, demonstrate promising results in increasing protection against TB in adults with latent infections...The pursuit of more effective TB vaccines, capable of providing broader protection across all age groups, is paramount. This effort not only aligns with the WHO's End TB Strategy but also offers hope for a future where TB is no longer a global health crisis.
|
